AAAAAA
Results:
1-20
|
Results: 20
Authors:
McKenna, F
Borenstein, D
Wendt, H
Wallemark, C
Lefkowith, JB
Geis, GS
Citation: F. Mckenna et al., Celecoxib versus diclofenac in the management of osteoarthritis of the knee - A placebo-controlled, randomised, double-blind comparison, SC J RHEUM, 30(1), 2001, pp. 11-18
Authors:
Williams, GW
Hubbard, RC
Yu, SS
Zhao, W
Geis, GS
Citation: Gw. Williams et al., Comparison of once-daily and twice-daily administration of celecoxib for the treatment of osteoarthritis of the knee, CLIN THER, 23(2), 2001, pp. 213-227
Authors:
Gimbel, JS
Brugger, A
Zhao, W
Verburg, KM
Geis, GS
Citation: Js. Gimbel et al., Efficacy and tolerability of celecoxib versus hydrocodone/acetaminophen inthe treatment of pain after ambulatory orthopedic surgery in adults, CLIN THER, 23(2), 2001, pp. 228-241
Authors:
Goldstein, JL
Correa, P
Zhao, WW
Burr, AM
Hubbard, RC
Verburg, KM
Geis, GS
Citation: Jl. Goldstein et al., Reduced incidence of gastroduodenal ulcers with celecoxib, a novel cyclooxygenase-2 inhibitor, compared to naproxen in patients with arthritis, AM J GASTRO, 96(4), 2001, pp. 1019-1027
Authors:
Williams, GW
Ettlinger, RE
Ruderman, EM
Hubbard, RC
Lonien, ME
Yu, SS
Zhao, W
Geis, GS
Citation: Gw. Williams et al., Treatment of osteoarthritis with a once-daily dosing regimen of celecoxib - A randomized, controlled trial, JCR-J CLIN, 6(2), 2000, pp. 65-74
Authors:
Bensen, WG
Zhao, SZ
Burke, TA
Zabinski, RA
Makuch, RW
Maurath, CJ
Agrawal, NM
Geis, GS
Citation: Wg. Bensen et al., Upper gastrointestinal tolerability of celecoxib, a COX-2 specific inhibitor, compared to naproxen and placebo, J RHEUMATOL, 27(8), 2000, pp. 1876-1883
Authors:
Karim, A
Tolbert, DS
Hunt, TL
Hubbard, RC
Harper, KM
Geis, GS
Citation: A. Karim et al., Celecoxib, a specific COX-2 inhibitor, has no significant effect on MTX pharmacokinetics or renal clearance in patients with RA (vol 26, pg 2539, 1999), J RHEUMATOL, 27(2), 2000, pp. 557-557
Authors:
Lefkowith, JB
Geis, GS
Silverstein, F
Citation: Jb. Lefkowith et al., Safety of celecoxib vs other nonsteroidal anti-inflammatory drugs - Reply, J AM MED A, 284(24), 2000, pp. 3123-3124
Authors:
Silverstein, FE
Faich, G
Goldstein, JL
Simon, LS
Pincus, T
Whelton, A
Makuch, R
Eisen, G
Agarwal, NM
Stenson, WF
Burr, AM
Zhao, WW
Kent, JD
Lefkowith, JB
Verburg, KM
Geis, GS
Citation: Fe. Silverstein et al., Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatorydrugs for osteoarthritis and rheumatoid arthritis - The CLASS study: A randomized controlled trial, J AM MED A, 284(10), 2000, pp. 1247-1255
Authors:
Karim, A
Tolbert, D
Piergies, A
Hubbard, RC
Harper, K
Wallemark, CB
Slater, M
Geis, GS
Citation: A. Karim et al., Celecoxib does not significantly alter the pharmacokinetics or hypoprothrombinemic effect of warfarin in healthy subjects, J CLIN PHAR, 40(6), 2000, pp. 655-663
Authors:
Leese, PT
Hubbard, RC
Karim, A
Isakson, PC
Yu, SS
Geis, GS
Citation: Pt. Leese et al., Effects of celecoxib, a novel cyclooxygenase-2 inhibitor, on platelet function in healthy adults: A randomized, controlled trial, J CLIN PHAR, 40(2), 2000, pp. 124-132
Authors:
Whelton, A
Schulman, G
Wallemark, C
Drower, EJ
Isakson, PC
Verburg, KM
Geis, GS
Citation: A. Whelton et al., Effects of celecoxib and naproxen on renal function in the elderly, ARCH IN MED, 160(10), 2000, pp. 1465-1470
Authors:
Goldstein, JL
Silverstein, FE
Agrawal, NM
Hubbard, RC
Kaiser, J
Maurath, CJ
Verburg, KM
Geis, GS
Citation: Jl. Goldstein et al., Reduced risk of upper gastrointestinal ulcer complications with celecoxib a novel COX-2 inhibitor, AM J GASTRO, 95(7), 2000, pp. 1681-1690
Authors:
Geis, GS
Citation: Gs. Geis, Update on clinical developments with celecoxib, a new specific COX-2 inhibitor: What can we expect?, J RHEUMATOL, 26, 1999, pp. 31-36
Authors:
Karim, A
Tolbert, DS
Hunt, TL
Hubbard, RC
Harper, KM
Geis, GS
Citation: A. Karim et al., Celecoxib, a specific COX-2 inhibitor, has no significant effect on methotrexate pharmacokinetics in patients with rheumatoid arthritis, J RHEUMATOL, 26(12), 1999, pp. 2539-2543
Authors:
Geis, GS
Citation: Gs. Geis, Update on clinical developments with celecoxib, a new specific COX-2 inhibitor: What can we expect?, SC J RHEUM, 28, 1999, pp. 31-37
Authors:
Cheatum, DE
Arvanitakis, C
Gumpel, M
Stead, H
Geis, GS
Citation: De. Cheatum et al., An endoscopic study of gastroduodenal lesions induced by nonsteroidal anti-inflammatory drugs, CLIN THER, 21(6), 1999, pp. 992-1003
Authors:
Emery, P
Zeidler, H
Kvien, TK
Guslandi, M
Naudin, R
Stead, H
Verburg, KM
Isakson, PC
Hubbard, RC
Geis, GS
Citation: P. Emery et al., Celecoxib versus diclofenac in long-term management of rheumatoid arthritis: randomised double-blind comparison, LANCET, 354(9196), 1999, pp. 2106-2111
Authors:
Simon, LS
Weaver, AL
Graham, DY
Kivitz, AJ
Lipsky, PE
Hubbard, RC
Isakson, PC
Verburg, KM
Yu, SS
Zhao, WW
Geis, GS
Citation: Ls. Simon et al., Anti-inflammatory and upper gastrointestinal effects of celecoxib in rheumatoid arthritis - A randomized controlled trial, J AM MED A, 282(20), 1999, pp. 1921-1928
Authors:
Bensen, WG
Fiechtner, JJ
McMillen, JI
Zhao, WW
Yu, SS
Woods, EM
Hubbard, RC
Isakson, PC
Verburg, KM
Geis, GS
Citation: Wg. Bensen et al., Treatment of osteoarthritis with celecoxib, a cyclooxygenase-2 inhibitor: A randomized controlled trial, MAYO CLIN P, 74(11), 1999, pp. 1095-1105
Risultati:
1-20
|